Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Pharmacologic Substance > Hypolipidemic Agents

Hypolipidemic Agents

Hypolipidemic Agents are a class of pharmaceutical compounds that help lower elevated levels of lipids, such as cholesterol and triglycerides, in the blood.
These agents work by inhibiting the production or absorption of lipids, or by enhancing their removal from the body.
They are commonly used to manage conditions like hyperlipidemia, which can lead to an increased risk of cardiovascular disease.
Reseaarchers can use PubCompare.ai's innovative platform to optimize their protocols and enhance the reproducibility of studies involving these important therapeutic agents.

Most cited protocols related to «Hypolipidemic Agents»

1
Validating a Metabolic Syndrome Severity Score
Cited 62 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2013
Adolescent Adult Age Groups BLOOD Cerebrovascular Accident Child Congestive Heart Failure C Reactive Protein Determination, Blood Pressure Diabetes Mellitus Ethnicity Feelings Glucose Heart Disease, Coronary High Density Lipoprotein Cholesterol Hispanics Homeostasis Households Hypolipidemic Agents Insulin Insulin Resistance Lipids Metabolic Syndrome X Mexican Americans Myocardial Infarction Obesity Pharmaceutical Preparations Phlebotomy Plant Roots Plasma Population Group Pressure, Diastolic Racial Groups Sulfur Surrogate Markers Triglycerides Uric Acid Waist Circumference
2
Belimumab for Systemic Lupus Erythematosus
Cited 18 times
In this phase 3, multicenter, randomized, double-blind, placebo-controlled trial, patients with SLE on SOC therapy were assigned to receive placebo, or belimumab 1 or 10 mg/kg by intravenous (IV) infusion over 1 hour on days 0, 14, and 28, and every 28 days through week 72. While the initiation of an immunosuppressive (IS) drug was prohibited during the trial, the addition of a new antimalarial (AM) drug and dose increases of concomitant IS or AM drugs were permitted until week 16. After week 16, however, the maximum doses of IS or AM drugs could be no greater than the higher of the baseline or week-16 dose. For corticosteroids, any dose was permitted through week 24; thereafter through week 44, the dose had to be within 25% or 5 mg of baseline. Between weeks 44 and 52, no increase over the higher of the baseline or week-44 dose was permitted. From weeks 52 through 68, the dose had to be within 25% or 5 mg of baseline, and an increase over the higher of the baseline or week-68 dose was prohibited after week 68. Prednisone could be reduced at the discretion of the investigator. As in the companion phase 3 BLISS-52 trial, the addition of a new biologic agent at any time, an inhibitor of the renin-angiotensin system after 4 months, or a new 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor after 6 months was prohibited; other antihypertensive or lipid-lowering agents were allowed during the study (17 (link)). The Safety of Estrogens in Lupus Erythematosus National Assessment–SLE Disease Activity Index (SELENA-SLEDAI) (18 (link)), Physician’s Global Assessment (PGA) (18 (link)), British Isles Lupus Assessment Group (BILAG) (19 (link),20 (link)), and SLE Flare Index (SFI) (21 (link)) were evaluated every 4 weeks (except weeks 56 and 64), as were AEs, vital signs, concomitant medications, and laboratory and pregnancy tests.
Furie R., Petri M., Zamani O., Cervera R., Wallace D.J., Tegzová D., Sanchez-Guerrero J., Schwarting A., Merrill J.T., Chatham W.W., Stohl W., Ginzler E.M., Hough D.R., Zhong Z.J., Freimuth W, & van Vollenhoven R.F. (2011). A Phase 3, Randomized, Placebo-Controlled Study of Belimumab, a Monoclonal Antibody That Inhibits BLyS, in Patients With Systemic Lupus Erythematosus. Arthritis and rheumatism, 63(12), 3918-3930.
Publication 2011
Adrenal Cortex Hormones Angiotensins Antihypertensive Agents Antimalarials belimumab Biological Factors Coenzyme A Estrogens Hypolipidemic Agents Immunosuppressive Agents Intravenous Infusion Lupus Vulgaris Oxidoreductase Patients Pets Pharmaceutical Preparations Physicians Placebos Prednisone Pregnancy Tests Renin Inhibitors Safety Signs, Vital Therapeutics
3
Genetic Determinants of Lipid Response to Fenofibrate
Cited 15 times
The National Heart, Lung, and Blood Institute GOLDN study, described in detail in previous publications [9 (link), 10 (link)], was designed to identify genetic determinants of lipid response to treatment with 160 mg of micronized fenofibrate once a day for three weeks. Briefly, Caucasian families with at least 2 siblings were recruited from the genetically homogeneous centers of the National Heart, Lung, and Blood Institute Family Heart study in Minneapolis, MN, and Salt Lake City, UT. Participants were asked to discontinue the use of lipid-lowering agents for at least 4 weeks, to fast for at least 8 hours prior to study visits, and to abstain from alcohol for at least 24 hours prior to study visits. The study protocol was approved by Institutional Review Boards at the University of Minnesota, University of Utah, and Tufts University/New England Medical Center.
Aslibekyan S., Kabagambe E.K., Irvin M.R., Straka R.J., Borecki I.B., Tiwari H.K., Tsai M.Y., Hopkins P.N., Shen J., Lai C.Q., Ordovas J.M, & Arnett D.K. (2012). A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the Genetics of Lipid Lowering Drug and Diet Network (GOLDN). Pharmacogenetics and Genomics, 22(3), 191-197.
Publication 2012
BLOOD Caucasoid Races Ethanol Ethics Committees, Research Fenofibrate Heart Hypolipidemic Agents Lipids Lung Sibling Sodium Chloride, Dietary
4
Gender Differences in Acute Stroke
Cited 14 times
Between January 2005 and January 2009, 1,055 consecutive patients with acute stroke (i.e., within 7 days after symptom onset) were identified at Soonchunhyang University Hospital. We separated patients according to gender and prospectively analyzed their baseline characteristics, mortality, and functional outcomes at discharge and at 3 months and 1 year after stroke onset. We compared the mean age, time delay from symptom onset to hospital arrival, and risk factors between the genders. The risk factors included past history of hypertension (previous diagnosis, current treatment, or blood pressures of ≥160/95 mmHg in at least two subsequent measurements), diabetes mellitus (previous diagnosis or current treatment with insulin or oral hypoglycemic medications, or a fasting plasma glucose level of ≥126 mg/dL in at least two subsequent measurements), hyperlipidemia (diagnosis or current treatment with lipid-lowering agents, or serum low-density lipoprotein concentration of ≥160 mg/dL), smoking (currently or previously), and potential cardioembolic source.
The existences of previous transient ischemic attack (acute neurological deficit of vascular origin, lasting <24 hours) and stroke (including ischemic or hemorrhagic stroke) were also analyzed. We also investigated compliance with medication for risk factors in those patients with at least one more risk factors. Stroke subtype was classified according to the Trial of Org 10,172 in Acute Stroke Treatment criteria.18 (link)
We analyzed various variables at admission and discharge. At admission, gender differences were assessed in stroke severity according to the National Institutes of Health Stroke Scale (NIHSS), and in the use of intravenous recombinant tissue plasminogen activator (rt-PA). At discharge, the duration of hospital stay, achievement of anticoagulation for high-risk patients of cardioembolic source, stroke severity, functional outcome on the modified Rankin scale (mRS), and mortality during hospitalization were analyzed. The initial neurologic deficits were categorized using the NIHSS into mild (score ≤7), moderate (score >7 and ≤16), and severe (score >16).
Functional outcome as determined by mRS score and mortality were followed up at 3 months and 1 year after stroke onset in the available survivors. The mRS scores were dichotomized into ≤2 (good functional outcome) and >2 (poor outcome). These assessments were made via telephone or face-to-face interview at outpatient clinic.
Univariate and multivariate analyses were performed with SPSS version 15.0 for Windows (SPSS Inc, Chicago, IL, USA). Univariate analysis was performed using the χ2 test for dichotomous variables and the t-test for continuous variables. The level of statistical significance was set at p<0.05. Multivariate analysis was carried out with a logistic regression model. Variables with a probability of p<0.1 in univariate analysis were included in the multivariate analysis. The results of the logistic regressions are presented using 95% confidence intervals (CIs). Other data are presented as mean±SD values except where stated otherwise.
Kim J.S., Lee K.B., Roh H., Ahn M.Y, & Hwang H.W. (2010). Gender Differences in the Functional Recovery after Acute Stroke. Journal of Clinical Neurology (Seoul, Korea), 6(4), 183-188.
Publication 2010
Acute Cerebrovascular Accidents Alteplase Birth Blood Vessel Cerebrovascular Accident Diabetes Mellitus Diagnosis Face Gender Glucose Hemorrhagic Stroke High Blood Pressures Hospitalization Hyperlipidemia Hypoglycemic Agents Hypolipidemic Agents Insulin Low-Density Lipoproteins Patient Discharge Patients Plasma Serum Survivors Transient Ischemic Attack
5
Multifactorial Determinants of Health Outcomes
Cited 11 times
Information on potential covariates was collected in 2006 and updated every 2 years thereafter, as detailed elsewhere (11 (link),12 ,16 (link),20 (link)). In brief, information on age, sex, smoking, alcohol intake, salt intake, physical activity, average monthly income, education level, and past self-reported medical history (e.g., hypertension, diabetes, and active treatment such as hypoglycemic agents, antihypertensive agents, lipid-lowering agents, and aspirin) was collected via questionnaire. Assessment of alcohol intake was determined as follows: light drinker, 0.1–0.4 servings/day for women and 0.1–0.9 servings/day for men; moderate drinker, 0.5–1.5 servings/day for women and 1–2 serving/day for men; heavy drinker, >1.5 servings/day for women and >2 serving/day for men; based on 15 g of alcohol per day. Height, weight, and blood pressure were measured by trained field workers (i.e., nurses) during the surveys. BMI was calculated as weight in kilograms divided by height in meters squared. Total cholesterol, triglycerides, HDL cholesterol (HDL-c), LDL cholesterol (LDL-c), creatinine, and hs-CRP were assessed by auto analyzer (Hitachi 747; Hitachi, Tokyo, Japan) at the central laboratory of Kailuan hospital. Estimated glomerular filtration rate (eGFR) was calculated by the Chronic Kidney Disease Epidemiology Collaboration creatinine equation (21 (link)).
Jin C., Chen S., Vaidya A., Wu Y., Wu Z., Hu F.B., Kris-Etherton P., Wu S, & Gao X. (2017). Longitudinal Change in Fasting Blood Glucose and Myocardial Infarction Risk in a Population Without Diabetes. Diabetes Care, 40(11), 1565-1572.
Publication 2017
Alcoholic Intoxication Antihypertensive Agents Aspirin Blood Pressure Cholesterol Cholesterol, beta-Lipoprotein Chronic Kidney Diseases C Reactive Protein Creatinine Diabetes Mellitus Ethanol Glomerular Filtration Rate High Blood Pressures High Density Lipoprotein Cholesterol Hypoglycemic Agents Hypolipidemic Agents Light Nurses Sodium Chloride, Dietary Triglycerides Woman Workers

Most recents protocols related to «Hypolipidemic Agents»

1
Comprehensive Cardiometabolic Risk Assessment
A case report form was developed to record general characteristics, clinical diagnosis, and biochemical examination. Waist circumference (WC) was measured at the middle point between the costal margin and iliac crest. BMI was calculated as body weight in kilograms divided by body height in meters squared (kg/m2). Smoking habit was categorized as current smoking, ever smoking, or no smoking. Current smoking was determined when subjects were smoking currently and more than one cigarette daily in at least one year continuously. Ever smoking was determined when subjects smoked more than one cigarette daily, but had quitted smoking at least one year before. Drinking habit was categorized as current drinking, ever drinking, or no drinking. Current drinking was determined when subjects were drinking liquor, beer or wine currently in at least one year. Ever drinking was determined when subjects drank previously, but had quitted drinking at least one year before. History of lipid disorders included that plasma total cholesterol was ≥ 5.7 mmol/l, or low-density lipoprotein cholesterol (LDL-C) was ≥ 3.6 mmol/l, or high-density lipoprotein cholesterol (HDL-C) < 1.04 mmol/l, triglyceride was ≥ 1.7 mmol/l, or treatment with antihyperlipidemic agents due to hyperlipidemia. Hypertension was diagnosed by systolic blood pressure (SBP) ≥ 140 mmHg, or diastolic blood pressure (DBP) ≥ 90 mmHg, or being actively treated with anti-hypertension drugs. Diabetes mellitus was diagnosed by a fasting plasma glucose ≥ 7.0 mmol/l, or by a random plasma glucose ≥ 11.1 mmol/l, or when they were actively receiving therapy using insulin or oral medications for diabetes. Chronic kidney disease was defined as an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m2.
Wang Y., Guo X., Zhang Y., Zhang R, & Li J. (2023). Different associations of general and abdominal obesity with upper and lower extremity artery disease among a community population in China. Nutrition & Metabolism, 20, 14.
Full text: Click here
Publication 2023
Amniotic Fluid Antihypertensive Agents Beer Body Height Body Weight Cholesterol Cholesterol, beta-Lipoprotein Chronic Kidney Diseases Costal Arch Diabetes Mellitus Glomerular Filtration Rate Glucose High Blood Pressures High Density Lipoprotein Cholesterol Hyperlipidemia Hypolipidemic Agents Iliac Crest Insulin Lipid Metabolism Disorders Pharmaceutical Preparations Plasma Pressure, Diastolic Systolic Pressure Therapeutics Triglycerides Waist Circumference Wine
2
Antidiabetic Drug Adherence Patterns
For each patient, all antidiabetic drugs prescribed during the follow-up were identified. The period covered by an individual prescription was calculated by dividing the total amount of the drug prescribed for the defined daily dose. For overlapping prescriptions, the patient was assumed to have taken all drugs contained in the first prescription before starting the second one. Adherence was measured by the cumulative number of days in which the drug was available divided by the days of the follow-up, i.e. by the proportion of days covered (PDC) by treatment [22 (link)]. We classified patients prescribed more than one antidiabetic drug class as “adherent” if they were covered by at least one drug prescription. Because information on drug therapies dispensed during hospitalization was not available, the exposure to antidiabetic treatment before hospital admission was assumed to be continued for the entire span of the-hospital stay [23 (link)]. Four categories of adherence with antidiabetic drug therapy were considered, i.e. very low (≤ 25%), low (26%-50%), intermediate (51%-75%) and high (> 75%) PDC values. These cut-off values were used because in previous studies on the Lombardy database these adherence levels showed a clear association with mortality among elderly patients in treatment with antihypertensive and lipid-lowering drugs [24 (link), 25 (link)].
Rea F., Savaré L., Valsassina V., Ciardullo S., Perseghin G., Corrao G, & Mancia G. (2023). Adherence to antidiabetic drug therapy and reduction of fatal events in elderly frail patients. Cardiovascular Diabetology, 22, 53.
Full text: Click here
Publication 2023
Aged Antidiabetics Antihypertensive Agents Hospitalization Hypolipidemic Agents Patients Pharmaceutical Preparations Pharmacotherapy
3
Antidiabetic Drug Adherence Patterns
For each patient, all antidiabetic drugs prescribed during the follow-up were identified. The period covered by an individual prescription was calculated by dividing the total amount of the drug prescribed for the defined daily dose. For overlapping prescriptions, the patient was assumed to have taken all drugs contained in the first prescription before starting the second one. Adherence was measured by the cumulative number of days in which the drug was available divided by the days of the follow-up, i.e. by the proportion of days covered (PDC) by treatment [22 (link)]. We classified patients prescribed more than one antidiabetic drug class as “adherent” if they were covered by at least one drug prescription. Because information on drug therapies dispensed during hospitalization was not available, the exposure to antidiabetic treatment before hospital admission was assumed to be continued for the entire span of the-hospital stay [23 (link)]. Four categories of adherence with antidiabetic drug therapy were considered, i.e. very low (≤ 25%), low (26%-50%), intermediate (51%-75%) and high (> 75%) PDC values. These cut-off values were used because in previous studies on the Lombardy database these adherence levels showed a clear association with mortality among elderly patients in treatment with antihypertensive and lipid-lowering drugs [24 (link), 25 (link)].
Rea F., Savaré L., Valsassina V., Ciardullo S., Perseghin G., Corrao G, & Mancia G. (2023). Adherence to antidiabetic drug therapy and reduction of fatal events in elderly frail patients. Cardiovascular Diabetology, 22, 53.
Full text: Click here
Publication 2023
Aged Antidiabetics Antihypertensive Agents Hospitalization Hypolipidemic Agents Patients Pharmaceutical Preparations Pharmacotherapy
4
First-Episode Major Depressive Disorder Patients
Participants were recruited at the psychiatric outpatient department of the First Hospital of Shanxi Medical University from 2015 to 2017. Inclusion criteria were as follows: (1) fulfilling DSM-IV criteria for MDD, diagnosed by two trained psychiatrists using the Structured Clinical Interview for DSM-IV Disorders (SCID); (2) 17-item Hamilton Depression Scale (HAMD) score of more than 23; (3) age 18-60 years old, Han nationality; (4) no prior medication, including antidepressant, antipsychotic drugs, thyroid hormone therapy, hypoglycemic agents, antihypertensive and lipid-lowering drugs; and (5) depression symptoms were first-episode and the disease duration of no more than 24 months. Exclusion criteria included: (1) pregnant or breastfeeding women; (2) concurrent DSM-IV axis I disorder including bipolar disorder, schizophrenia, and schizoaffective or severe medical conditions; (3) substance use disorder except for tobacco; and (4) unwillingness to provide informed consent.
All participants provided written informed consent. This study was approved by the Institutional Review Board (IRB) of the First Hospital of Shanxi Medical University (No. 2016-Y27).
Peng P., Wang Q., Lang X., Liu T, & Zhang X.Y. (2023). Clinical symptoms, thyroid dysfunction, and metabolic disturbances in first-episode drug-naïve major depressive disorder patients with suicide attempts: A network perspective. Frontiers in Endocrinology, 14, 1136806.
Full text: Click here
Publication 2023
Antidepressive Agents Antihypertensive Agents Antipsychotic Agents Bipolar Disorder Depressive Symptoms Epistropheus Ethics Committees, Research Hypoglycemic Agents Hypolipidemic Agents Outpatients Pharmaceutical Preparations Psychiatrist Schizophrenia Therapeutics Thyroid Hormones Tobacco Use Disorder Woman
5
Dietary Fiber Intervention for Youth Type 2 Diabetes
This was a pilot randomized double-blind crossover trial in Y-T2DM (Supplementary Figure S1). Youth aged 10–25 years, diagnosed with Y-T2DM by the American Diabetes Association criteria (27 (link)), Tanner stage IV or V, with Hemoglobin A1c (HbA1c) ≤8% were recruited to participate in this MIGHTY-Fiber Study. Exclusion criteria included: positive diabetes related autoantibodies (GAD-65 and IA-2 autoantibodies); consumption of ≥ 2 or more servings of ≥6 oz of yogurt per day; chronic GI disease; gastric bypass surgery; cancer diagnosis or auto-immune disease; chronic insulin therapy within 3 months of the study; or use of antibiotics, immunosuppressants, hormonal contraceptives, lipid-lowering agents, proton-pump inhibitors, supraphysiologic systemic steroids, cholesterol medications, prebiotics, or probiotics in the previous month at time of screening.
Dixon S.A., Mishra S., Dietsche K.B., Jain S., Mabundo L., Stagliano M., Krenek A., Courville A., Yang S., Turner S.A., Meyers A.G., Estrada D.E., Yadav H, & Chung S.T. (2023). The effects of prebiotics on gastrointestinal side effects of metformin in youth: A pilot randomized control trial in youth-onset type 2 diabetes. Frontiers in Endocrinology, 14, 1125187.
Full text: Click here
Publication 2023
Antibiotics Autoantibodies Autoimmune Diseases Cholesterol Contraceptive Agents Diabetes Mellitus Diagnosis Disease, Chronic Fibrosis Gastric Bypass Gastrointestinal Diseases glutamate decarboxylase 2 (pancreatic islets and brain, 65kDa) protein, human Hemoglobin A, Glycosylated Hypolipidemic Agents IA-2 autoantibody Immunosuppressive Agents Insulin Malignant Neoplasms Operative Surgical Procedures Pharmaceutical Preparations Prebiotics Probiotics Proton Pump Inhibitors Steroids Therapeutics Yogurt Youth

Top products related to «Hypolipidemic Agents»

1
Sas version 9 by SAS Institute
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
2
Sas 9 by SAS Institute
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
3
Au5800 by Beckman Coulter
Sourced in United States, Japan, Germany, United Kingdom, China, Italy, Canada
The AU5800 is a chemistry analyzer designed for high-throughput clinical laboratory testing. It features advanced optics and automation to provide reliable and efficient sample processing. The core function of the AU5800 is to perform a variety of clinical chemistry tests, including immunoassays, on patient samples.
4
Sas statistical software by SAS Institute
Sourced in United States, Austria, Japan, Cameroon
SAS statistical software is a comprehensive data analysis and visualization tool. It provides a wide range of statistical procedures and analytical capabilities for managing, analyzing, and presenting data. The software is designed to handle large and complex datasets, allowing users to perform advanced statistical modeling, regression analysis, and data mining tasks. The core function of the SAS statistical software is to enable users to extract insights and make data-driven decisions.
5
Spss version by IBM
Sourced in United States, United Kingdom, Japan, Germany
SPSS is a software package used for statistical analysis. It provides a graphical user interface and a robust set of tools for data manipulation, analysis, and visualization. SPSS is designed to handle a wide range of data types and supports a variety of statistical techniques, including regression analysis, factor analysis, and time series analysis.
6
Empower r by X&Y Solutions
Sourced in United States
The Empower (R) is a lab equipment product that serves as a precision instrument for analytical tasks. It provides accurate and reliable data measurement and analysis capabilities.
7
Hem 705cp e by Omron
The HEM-705CP-E is a blood pressure monitor designed for professional use in medical settings. It is equipped with an intelligent measurement algorithm and a large LCD display to provide accurate and reliable blood pressure readings. The device is compact and portable, making it suitable for use in various healthcare environments.
8
Cobas c501 by Roche
Sourced in Switzerland, Germany, United States, Japan, Denmark, France, Sweden
The Cobas c501 is a clinical chemistry analyzer developed by Roche. It is designed for routine and specialized in vitro diagnostic testing in a laboratory setting. The Cobas c501 performs a wide range of biochemical and immunochemical analyses on various sample types.
9
Spss version 22 by IBM
Sourced in United States, Japan, United Kingdom, Austria, Germany, Czechia, Belgium, Denmark, Canada
SPSS version 22.0 is a statistical software package developed by IBM. It is designed to analyze and manipulate data for research and business purposes. The software provides a range of statistical analysis tools and techniques, including regression analysis, hypothesis testing, and data visualization.

More about "Hypolipidemic Agents"

Hypolipidemic agents, also known as lipid-lowering drugs or cholesterol-lowering agents, are a class of pharmaceutical compounds used to manage elevated levels of lipids, such as cholesterol and triglycerides, in the blood.
These agents work by inhibiting the production or absorption of lipids, or by enhancing their removal from the body.
They are commonly used to treat conditions like hyperlipidemia, which can increase the risk of cardiovascular disease.
Researchers can utilize PubCompare.ai's innovative platform to optimize their research protocols and enhance the reproducibility of studies involving hypolipidemic agents.
The AI-driven comparisons provided by PubCompare.ai can help locate the best protocols and products from literature, pre-prints, and patents, streamlining the research process and unlocking new insights.
Hypolipidemic agents are an important therapeutic class, and their study often involves the use of statistical software like SAS version 9.4, SAS 9.4, SPSS version 22.0, and Empower (R).
These tools can be used to analyze data and support the development of new hypolipidemic agents, as well as the optimization of existing ones.
Additionally, laboratory equipment like the AU5800, HEM-705CP-E, and Cobas c501 analyzers may be used to measure lipid levels and evaluate the efficacy of hypolipidemic agents in clinical and research settings.
By leveraging the latest technologies and innovative platforms like PubCompare.ai, researchers can enhance the quality and reproducibility of their studies on these crucial therapeutic agents.